Thursday, September 15, 2016

Zegerid


Zegerid is a brand name of omeprazole/sodium bicarbonate, approved by the FDA in the following formulation(s):


ZEGERID (omeprazole; sodium bicarbonate - capsule; oral)



  • Manufacturer: SANTARUS

    Approval date: February 27, 2006

    Strength(s): 20MG;1.1GM [AB], 40MG;1.1GM [RLD][AB]

ZEGERID (omeprazole; sodium bicarbonate - for suspension; oral)



  • Manufacturer: SANTARUS

    Approval date: June 15, 2004

    Strength(s): 20MG/PACKET;1.68GM/PACKET


  • Manufacturer: SANTARUS

    Approval date: December 21, 2004

    Strength(s): 40MG/PACKET;1.68GM/PACKET [RLD]

Has a generic version of Zegerid been approved?


A generic version of Zegerid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zegerid and have been approved by the FDA:


OMEPRAZOLE AND SODIUM BICARBONATE (omeprazole; sodium bicarbonate capsule; oral)



  • Manufacturer: PAR PHARM

    Approval date: May 25, 2010

    Strength(s): 20MG;1.1GM [AB], 40MG;1.1GM [AB]

Note: No generic formulation of the following product is available.


  • omeprazole; sodium bicarbonate - for suspension; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zegerid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Omeprazole solution and method for using same
    Patent 5,840,737
    Issued: November 24, 1998
    Inventor(s): Phillips; Jeffrey Owen
    Assignee(s): The Curators of the University of Missouri
    A pharmaceutical composition includes an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier comprising a bicarbonate salt of a Group IA metal. A method for treating and/or preventing gastrointestinal conditions by administering to a patient a pharmaceutical composition including an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal wherein the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal. A pharmaceutical composition for making a solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof includes omeprazole or other substituted benzimidazoles and derivatives thereof and a bicarbonate salt of a Group IA metal in a form for convenient storage whereby when the composition is dissolved in aqueous solution, the resulting solution is suitable for enteral administration.
    Patent expiration dates:

    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS


    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS


    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER




  • Substituted benzimidazole dosage forms and method of using same
    Patent 6,489,346
    Issued: December 3, 2002
    Inventor(s): Jeffrey Owen; Phillips
    Assignee(s): The Curators of the University of Missouri
    There is provided a solid pharmaceutical composition in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form includes a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition.
    Patent expiration dates:

    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Substituted benzimidazole dosage forms and method of using same
    Patent 6,645,988
    Issued: November 11, 2003
    Inventor(s): Jeffrey O.; Phillips
    Assignee(s): Curators of the University of Missouri
    The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form; and a kit for the preparation of a liquid oral pharmaceutical composition.
    Patent expiration dates:

    • July 16, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Substituted benzimidazole dosage forms and methods of using same
    Patent 6,699,885
    Issued: March 2, 2004
    Inventor(s): Jeffrey O.; Phillips
    Assignee(s): The Curators of the University of Missouri
    Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
    Patent expiration dates:

    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS


    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER


    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS




  • Substituted benzimidazole dosage forms and method of using same
    Patent 6,780,882
    Issued: August 24, 2004
    Inventor(s): Jeffrey O.; Phillips
    Assignee(s): The Curators of the University of Missouri
    There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, is present in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form can be non-enteric coated and can be in the form of a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition of the present invention.
    Patent expiration dates:

    • July 16, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Substituted benzimidazole dosage forms and method of using same
    Patent 7,399,772
    Issued: July 15, 2008
    Inventor(s): Phillips; Jeffrey Owen
    Assignee(s): Curators of the University of Missouri
    The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor and at least one buffering agent. Also provided is a pharmaceutical composition further comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and, a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules.
    Patent expiration dates:

    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS


    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER


    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS



See also...

  • Zegerid Consumer Information (Drugs.com)
  • Zegerid Consumer Information (Wolters Kluwer)
  • Zegerid Powder Packets Consumer Information (Wolters Kluwer)
  • Zegerid Consumer Information (Cerner Multum)
  • Zegerid Advanced Consumer Information (Micromedex)
  • Omeprazole/Sodium Bicarbonate Consumer Information (Wolters Kluwer)
  • Omeprazole/Sodium Bicarbonate Powder Packets Consumer Information (Wolters Kluwer)
  • Omeprazole and sodium bicarbonate Consumer Information (Cerner Multum)
  • Omeprazole and sodium bicarbonate Advanced Consumer Information (Micromedex)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)